206 filings
8-K
ALBO
Albireo Pharma Inc
2 Mar 23
Completion of Acquisition or Disposition of Assets
4:27pm
8-K
ALBO
Albireo Pharma Inc
14 Feb 23
Other Events
8:38am
8-K
ALBO
Albireo Pharma Inc
9 Jan 23
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
6:05am
8-K
ALBO
Albireo Pharma Inc
6 Dec 22
Departure of Directors or Certain Officers
8:37am
8-K
ALBO
Albireo Pharma Inc
8 Nov 22
Albireo Reports Q3 2022 Financial Results and Business Update
4:07pm
8-K
h17ut2m 7vkq04
11 Oct 22
Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay® (odevixibat) in Alagille Syndrome
8:25am
8-K
q2jaad7bpn16
22 Sep 22
Albireo Announces $115 Million Royalty Monetization Agreement with Sagard
8:35am
8-K/A
jd4esvkn
22 Aug 22
Departure of Directors or Certain Officers
4:18pm
8-K
fa5ih
15 Aug 22
Entry into a Material Definitive Agreement
6:37pm
8-K
jal36uid
15 Aug 22
Albireo Reports Q2 2022 Financial Results and Business Update
4:31pm
8-K
hhsqehz
10 Aug 22
Albireo Appoints New Members to Board of Directors
8:37am
8-K
y6ewi3 e3
29 Jul 22
Termination of a Material Definitive Agreement
4:01pm
8-K
7i76mvtqmt
17 Jun 22
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
87f003jb
16 May 22
Albireo Reports Q1 2022 Financial Results and Business Update
12:00am
8-K
keluoix 11plin
1 Mar 22
Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update
8:43am
8-K/A
n8j5ul ew
5 Jan 22
Departure of Directors or Certain Officers
10:32am
8-K
hc0d6z75r09hgko9mkf2
5 Jan 22
Results of Operations and Financial Condition
8:45am
8-K
kuwi0f3t66hshgivdwu
9 Dec 21
Albireo Announces Changes to R&D Organization
9:32am
8-K
syhkpv elv
4 Nov 21
Albireo Reports Q3 Financial Results and Business Update
8:45am
8-K
t087fes8pcs2o9c
7 Sep 21
Entry into a Material Definitive Agreement
8:54am